Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/THBS1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/THBS1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/THBS1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/THBS1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/THBS1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001063119 | Oral cavity | EOLP | epithelial cell migration | 80/2218 | 357/18723 | 1.03e-08 | 4.97e-07 | 80 |
GO:009013219 | Oral cavity | EOLP | epithelium migration | 80/2218 | 360/18723 | 1.52e-08 | 6.97e-07 | 80 |
GO:000940822 | Oral cavity | EOLP | response to heat | 35/2218 | 110/18723 | 2.23e-08 | 9.47e-07 | 35 |
GO:004804115 | Oral cavity | EOLP | focal adhesion assembly | 30/2218 | 87/18723 | 2.87e-08 | 1.16e-06 | 30 |
GO:009013019 | Oral cavity | EOLP | tissue migration | 80/2218 | 365/18723 | 2.89e-08 | 1.16e-06 | 80 |
GO:000268323 | Oral cavity | EOLP | negative regulation of immune system process | 91/2218 | 434/18723 | 3.12e-08 | 1.24e-06 | 91 |
GO:005189317 | Oral cavity | EOLP | regulation of focal adhesion assembly | 25/2218 | 66/18723 | 4.84e-08 | 1.81e-06 | 25 |
GO:009010917 | Oral cavity | EOLP | regulation of cell-substrate junction assembly | 25/2218 | 66/18723 | 4.84e-08 | 1.81e-06 | 25 |
GO:004854526 | Oral cavity | EOLP | response to steroid hormone | 75/2218 | 339/18723 | 5.18e-08 | 1.92e-06 | 75 |
GO:200123625 | Oral cavity | EOLP | regulation of extrinsic apoptotic signaling pathway | 42/2218 | 151/18723 | 7.31e-08 | 2.61e-06 | 42 |
GO:009719125 | Oral cavity | EOLP | extrinsic apoptotic signaling pathway | 54/2218 | 219/18723 | 9.74e-08 | 3.36e-06 | 54 |
GO:004315423 | Oral cavity | EOLP | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 27/2218 | 78/18723 | 1.28e-07 | 4.22e-06 | 27 |
GO:000716017 | Oral cavity | EOLP | cell-matrix adhesion | 56/2218 | 233/18723 | 1.44e-07 | 4.68e-06 | 56 |
GO:007135623 | Oral cavity | EOLP | cellular response to tumor necrosis factor | 55/2218 | 229/18723 | 1.90e-07 | 6.02e-06 | 55 |
GO:015011618 | Oral cavity | EOLP | regulation of cell-substrate junction organization | 25/2218 | 71/18723 | 2.54e-07 | 7.85e-06 | 25 |
GO:200011723 | Oral cavity | EOLP | negative regulation of cysteine-type endopeptidase activity | 28/2218 | 86/18723 | 3.25e-07 | 9.60e-06 | 28 |
GO:003461224 | Oral cavity | EOLP | response to tumor necrosis factor | 58/2218 | 253/18723 | 4.79e-07 | 1.32e-05 | 58 |
GO:000926622 | Oral cavity | EOLP | response to temperature stimulus | 45/2218 | 178/18723 | 5.23e-07 | 1.40e-05 | 45 |
GO:007190023 | Oral cavity | EOLP | regulation of protein serine/threonine kinase activity | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
GO:003300212 | Oral cavity | EOLP | muscle cell proliferation | 56/2218 | 248/18723 | 1.25e-06 | 3.00e-05 | 56 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THBS1 | SNV | Missense_Mutation | | c.3229C>T | p.Arg1077Trp | p.R1077W | P07996 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.2476N>G | p.Met826Val | p.M826V | P07996 | protein_coding | tolerated(0.44) | benign(0.015) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.1472N>A | p.Ile491Asn | p.I491N | P07996 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | rs576321057 | c.2318G>A | p.Arg773His | p.R773H | P07996 | protein_coding | deleterious(0.05) | possibly_damaging(0.591) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD |
THBS1 | SNV | Missense_Mutation | novel | c.905N>T | p.Thr302Ile | p.T302I | P07996 | protein_coding | tolerated(0.05) | benign(0.216) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1869_1870insA | p.Phe624IlefsTer25 | p.F624Ifs*25 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1871_1872insTGTGACCATCAACTCTGTA | p.Thr625ValfsTer30 | p.T625Vfs*30 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.236_237insCTTAA | p.Asp80LeufsTer17 | p.D80Lfs*17 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Nonsense_Mutation | novel | c.237_238insAGTTGAGAGATTTAGCAGCTCAAAAATGTGACCT | p.Asp80SerfsTer2 | p.D80Sfs*2 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.988_989insTTCCAGCCCTGCCATCCGCACTAACTACATTGGCCACAAGACA | p.Glu330ValfsTer19 | p.E330Vfs*19 | P07996 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2&APOS;-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | METHYLCELLULOSE | METHYLCELLULOSE | 9016860 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PROTEIN KINASE C INHIBITOR | | 9223624 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SIMVASTATIN | SIMVASTATIN | 10543307 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | UVB | | 14962109 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ABT-510 | ABT-510 | |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | VESNARINONE | VESNARINONE | 15356428 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ALL-TRANS RETINOIC ACID | | 9447832 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 1430209 |